Sarepta Therapeut…
USUSDSarepta Therapeutics Inc (US:SRPT) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- sarepta.com
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège social
- Cambridge, United States
- PDG
- Michael E. Severino
- Employés
- 835
- Fondée
- 1980
- Actions en circulation
- 105.63 M au 2026-07-31
- Flottant
- 100.54 M
- Capitalisation boursière
- 1.86 Md USD
- Initiés
- 4.89%
- Investisseurs institutionnels
- 104.07%
- Secteur d'activité (SIC)
- Pharmaceutical Preparations
- ISIN
- US8036071004
- LEI
- 549300IKDPIED8J8IG21
- Taux de distribution
- 0%
- FCF
- 81.8 M USD
- Dette
- 848 M USD3.4 ans de FCF
- Ancienneté du dividende
- —
- Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 30.06.2026 (le dernier rapport de l'entreprise).
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Dividendes
Aucun versement de dividendes n'a été trouvé (vérifié le 10.10.2026). L'entreprise ne verse probablement pas de dividendes.
Actualités de cette semaine
Pas encore d'actualités du site de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| Blackrock Inc. | 17.98% | 18.99 M | 2026-06-30 |
| State Street Corporation | 8.44% | 8.92 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 7.93% | 8.38 M | 2026-06-30 |
| iShares Trust-iShares Co… | 6.09% | 6.44 M | 2026-08-31 |
| First TRT Exch-Trd Fd.-F… | 4.52% | 4.78 M | 2026-08-31 |
| SPDR SERIES TRUST-State… | 4.45% | 4.7 M | 2026-08-31 |
| Two Sigma Investments, L… | 4.35% | 4.6 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.35% | 4.59 M | 2026-06-30 |
| First Trust Advisors LP | 4.13% | 4.37 M | 2026-06-30 |
| AQR Capital Management,… | 4.1% | 4.33 M | 2026-06-30 |
| BARRY RICHARD J (Directo… | ≈3.06% | 3.23 M | 2026-06-04 |
| VANGUARD INDEX FUNDS-Van… | 3.02% | 3.19 M | 2026-06-30 |
| Geode Capital Management… | 2.62% | 2.77 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.52% | 2.66 M | 2026-08-31 |
| Erste Asset Management G… | 2.43% | 2.57 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 2.3 M | 2026-06-30 |
| Marshall Wace LLP | 2.09% | 2.21 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.26% | 1.33 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.14% | 1.2 M | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.08% | 1.14 M | 2026-07-31 |
| Federated Hermes Equity… | 1.05% | 1.11 M | 2026-07-31 |
| INGRAM DOUGLAS S (Chief… | ≈0.88% | 929 391 | 2025-12-05 |
| SEVERINO MICHAEL E (Chie… | ≈0.72% | 756 104 | 2026-07-28 |
| CHAMBERS MICHAEL ANDREW… | ≈0.48% | 504 027 | 2026-06-04 |
| RODINO-KLAPAC LOUISE (Of… | ≈0.22% | 227 670 | 2026-02-27 |
| BEHRENS M KATHLEEN (Dire… | ≈0.21% | 224 357 | 2026-06-04 |
| ESTEPAN IAN MICHAEL (Chi… | ≈0.19% | 204 699 | 2026-02-27 |
| ROTHFUSS CRISTIN (Genera… | ≈0.13% | 139 985 | 2025-09-03 |
| WONG RYAN HO-YAN (Chief… | ≈0.13% | 136 203 | 2025-09-03 |
| NICAISE CLAUDE (Director… | ≈0.05% | 48 407 | 2026-06-04 |
